⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156793 | 1.00 | — | — | |
| SCHEMBL30945105 | 0.97 | — | — | |
| SCHEMBL6267496 | 0.78 | ALDH1A1 (0.46) | — | |
| SCHEMBL1303361 | 0.75 | — | — | |
| SCHEMBL29833727 | 0.75 | — | — | |
| SCHEMBL27790861 | 0.72 | — | — | |
| SCHEMBL6897272 | 0.72 | — | — | |
| SCHEMBL30185333 | 0.72 | — | — | |
| SCHEMBL28464108 | 0.71 | — | — | |
| SCHEMBL28454505 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445479-B2 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120252785-A1 | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8222244-B2 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973031-B2 | Leukemia therapy ;myelodyspastic syndrome | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20050020570-A1 | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2005-01-27 | — | — | US | disclosed |